Document:

SECURED
      PROMISSORY NOTE

    

    
      	$165,000 	
              JANUARY
                31,
                2007 

            

    

    

     FOR
      VALUE
      RECEIVED,
      POWER
      TECHNOLOGY, INC., a Nevada corporation whose address is 5300 Memorial Drive,
      Suite 700, Houston, Texas 77007 ("Maker"), promises to pay to the order of
      CSI
      BUSINESS FINANCE, INC., a Delaware corporation ("Payee"), in lawful money of
      the
      United States of America, the principal sum of up to ONE
      HUNDRED AND SIXTY FIVE THOUSAND AND 00/100 DOLLARS ($165,000.00).
      All
      principal and any interest hereunder shall be payable at 109 North Post Oak
      Lane, Suite 422, Houston, Texas, 77024, or such other place that Payee may
      hereinafter designate in writing.

    

    This
      Note
      shall be funded as follows: $75,000 shall be funded on January 31, 2007. If
      prior to March 1, 2007, Maker’s shareholders approve and ratify an amendment to
      the Articles of Incorporation of Maker to change the number of the authorized
      shares of Common Stock from 100,000,000 shares to 750,000,000 shares, then
      $45,000 shall be funded on March 1, 2007, and $45,000 will be funded on April
      1,
      2007.

     

    Principal
      under this note shall bear interest at the rate of eighteen percent (18%) per
      annum from the date of funding until paid in full. Accrued interest shall be
      due
      and payable on the 1st
      day of
      March , 2007, and on the 1st
      day of
      each subsequent month during the term hereof. All principal and interest under
      this Note shall be paid in full on June 30, 2007. All interest that shall accrue
      in accordance herewith on the indebtedness evidenced by this Note shall be
      computed on the basis of a year of 365 days.

    

    Each
      of
      the following events shall be herein referred to as an "Event of Default":
      (i)
      the failure to make payment of any of the principal or interest hereunder when
      due or on demand by payee, (ii) the filing of a petition in bankruptcy by Maker,
      (iii) the assignment of assets for the benefit of creditors of Maker, or (iv)
      the failure of the company to hold a shareholder meeting approving the issuance
      of up to 750 million common shares of the company’s common stock no later than
      February 28, 2007. It is especially agreed, that upon the occurrence of an
      Event
      of Default, Payee or any other holder hereof at any time thereafter may, at
      its
      option, (a) declare the entire unpaid principal of and accrued interest on
      this
      Note immediately due and payable and upon notice to Maker and failure to cure,
      the same shall become and shall be immediately due and payable; and (b) take
      any
      and all other actions available to Payee or any holder under this Note or any
      document given to secure this Note, at law, in equity or otherwise. The failure
      of the holder hereof to exercise any of the foregoing options shall not
      constitute a waiver of the right to exercise the salad upon the occurrence
      of a
      subsequent default.

    

    In
      addition to all principal and accrued interest on this Note, Maker agrees to
      pay
      (i) all reasonable costs and, expenses incurred by all owners and holders of
      this Note in collecting this Note through reorganization, bankruptcy,
      receivership or any other proceeding and (ii) reasonable attorney's fees when
      and if this Note is placed in the hands of an attorney for collection after
      default.

    

    It
      is the
      intention of the parties hereto to conform, strictly to applicable usury laws
      as
      in effect from time to time during the term of this Note. Accordingly, if any
      transaction or transactions contemplated hereby would be usurious under
      applicable law (including the laws of the United States of America, or of any
      other jurisdiction whose laws may be applicable), then, in that event,
      notwithstanding anything to the contrary in this Note, it is agreed as follows:
      (i) the provisions of this paragraph shall govern and control; (ii) the
      aggregate of an interest under applicable laws that is contracted for, charged
      or received under this Note shall under no circumstances exceed the maximum
      amount of interest allowed by applicable law, and any excess shall be promptly
      refunded to Maker by Payee (or, if such consideration shall have been paid
      in
      full, such excess shall be promptly refunded to Maker by Payee); (iii,) neither
      Maker nor any other person or entity now or hereafter liable in connection
      with
      this Note shall be obligated to pay the amount of such interest to the extent
      that it is in excess of the maximum interest permitted by the applicable usury
      laws; and. (iv) the effective rate of interest shall be IPSO FACTO reduced
      to
      the maximum lawful interest rate.

    

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    Maker
      shall have the privilege to prepay this Note at any time, and from time to
      time,
      in whole or part, without penalty or fee. Any prepayment of principal under
      this
      Note shall include accrued interest to the date of prepayment on the principal
      amount being prepaid.

    

    Maker
      and
      any other co-makers, endorsers, guarantors and sureties severally (i) waive
      notice (including, but not limited to, notice of protest, notice of dishonor
      and
      notice of intent to accelerate or notice of acceleration), demand, presentment
      of payment, protest and filing of suit for the purpose of fixing liability,
      (ii)
      consent that the time of payment hereof may be extended without notice
      to
      them or any of them, (iii) expressly agree that it will not be necessary for
      any
      holder hereof, in order to enforce payment of this Note by them, to first
      institute suit or exhaust its remedies against Maker or any others liable here
      for, or to enforce its rights against any security here for, and (iv) consent
      to
      any extensions or postponements of time of payment of this Note
      or
      any other indulgences with respect hereto without notice thereof to any of
      them.

    

    This
      Note
      is secured by that certain Stock Pledge Agreement of even date herewith executed
      by B.J. Walter in favor of Payee covering the pledge of 9,971,604 shares of
      fully paid and non-assessable shares of common stock of Maker represented by
      certificate numbers 5967, 10099, and 10015.

    

    IN
      WITNESS WHEREOF, Maker has executed this Note as of the date set forth
      above.

     

    
      	 	 	 
	 	POWER TECHNOLOGY, INC.
	 
 	 
 	 
 
	 	By:  	
              /s/
                Bernard J.
                Walter

            
	 	 	 
	 	Title: 	
              PresidentVioQuest

                PHARMACEUTICALS,
                  INC.

              

      

    

     

    Exhibit
      10.1

     

    January
      31, 2007

    

    Edward
      C.
      Bradley, M.D.

    323
      Fieldstone Drive

    New
      Hope,
      PA 18938

    

    Dear
      Dr.
      Bradley:

    

    On
      behalf
      of VioQuest Pharmaceuticals, Inc. (the “Company”), I am pleased to extend to you
      this conditional offer of employment as the Company’s Chief Scientific and
      Medical Officer. This letter (the “Letter”) shall confirm our understanding as
      to the terms of your employment with the Company.

    

    
      
        	
              	1.	
                We
                  intend that your employment will commence February 1, 2007, or
                  another
                  mutually agreed upon date (“Effective Date”). You will be entitled to
                  receive an annual base salary equal to $330,000 (gross, less legally
                  required withholding and other required deductions, and any deductions
                  that you voluntarily authorize in writing), payable on a semi-monthly
                  basis. In addition, you will be eligible for a target bonus of
                  20% of your
                  base salary based on personal performance, and an additional 10%
                  based on
                  Company performance. Thirty days from the Effective Date, your
                  bonus
                  objectives for 2007 will be determined by you and the President
                  and CEO.
                  Your 2007 bonus will be prorated based upon your effective start
                  date.
                  

              

      

    

    

    
      
        	
              	2.	
                You
                  shall be entitled to receive a stock option grant entitling you
                  to
                  purchase 700,000 shares of the Company’s Common Stock at a per share price
                  equal to the greater of (a) $0.54 or (b) 105% of the closing bid
                  price of
                  the Company’s Common Stock on the OTC Bulletin Board on the Effective Date
                  (the “Options”) (subject to adjustment for splits and/or other capital
                  restructuring), such Options to vest as follows:
                  

              

      

    

    

    (a) 
       233,000 of the Options will vest on the date that is one year from the
      Effective Date;

     

    (b) 
       233,000 of the Options will vest on the date that is two years from the
      Effective Date; 

     

    (c) 
       234,000 of the Options will vest on the date that is three years from the
      Effective Date; 

    

    With
      the
      exception of the foregoing terms described above, all terms of the Options
      will
      be consistent with Company’s 2003 stock option plan. Options will only vest if
      you are an employee of the Company. Upon your termination, unvested options
      will
      be deemed expired. The stock option will be evidenced by a separate agreement
      to
      be entered into by you and the Company, which will incorporate the terms of
      the
      Company’s 2003 stock option plan and otherwise provide the terms outlined in
      this letter.

    

      VioQuest
        Pharmaceuticals, Inc.

      180
        Mt. Airy Road, Suite 102

      Basking
        Ridge, NJ 07920

      Telephone:
        +1 908 766 4400 Fax: +1 908 766 4455 

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

          
            	
                    

                  	
                     

                  	
                    VioQuest

                    PHARMACEUTICALS,
                      INC.

                  

          

        

      

    

    

    

    In
      the
      event the Company completes a transaction in which it sells the assets or stock
      of VioQuest Pharmaceuticals, Inc. resulting in a change of control of the
      Company (other than a sale of the stock or assets of the Company’s Chiral Quest
      subsidiary) then the vesting terms of the stock options shall accelerate and
      all
      shares of common stock shall become immediately exercisable. 

    

    
      
        	
              	4.	
                You
                  shall be reimbursed for all of your pre-approved out-of-pocket
                  expenses
                  incurred in connection with the Company’s business.
                  

              

      

    

    

    
      
        	
              	5.	
                You
                  will be entitled to participate in the full benefits package which
                  includes medical, dental, life and travel insurances, as well as
                  the
                  Company’s 401(K) program pursuant to the group policy of the Company.
                  

              

      

    

    

    
      
        	
              	6.	
                Even
                  though some provisions in this offer refer to future dates, they
                  are only
                  reference points for certain events that are scheduled for as long
                  as you
                  are employed. Your employment will be for an indefinite term. The
                  Company
                  makes no guarantee, or express or implied contract, of definite
                  or
                  continued employment, and nothing in this letter modifies or is
                  intended
                  to modify your at-will employment relationship with the Company.
                  Although
                  your job duties, title, compensation and benefits, and the Company’s
                  policies may change from time-to-time, only a document signed by
                  you and
                  the CEO of the Company may modify the at will employment relationship.
                  Your employment will also be subject to the CEO’s general satisfaction
                  with your work performance. You may terminate your employment with
                  the
                  Company, for any reason, upon 10 days notice.

              

      

    

    

    
      
        	
              	7.	
                If
                  your employment is terminated by the Company for reasons other
                  than
                  “cause,” the Company shall continue to pay your base salary for a period
                  of six (6) months following such termination. Cause is defined
                  as the
                  conviction of a felony, theft or embezzlement of Company property,
                  or the
                  commission of an act involving moral turpitude that materially
                  and
                  adversely affects the Company’s reputation and business prospects, or the
                  failure to substantially perform your material duties and responsibilities
                  of your employment, which failure is not cured within thirty (30)
                  days
                  after written notice from the Company specifying the act of nonperformance
                  or within such longer period (but no longer than ninety (90) days
                  in any
                  event) as is reasonably required to cure such
                  nonperformance.

              

      

    

    

    
      
        	
              	8.	
                If
                  your employment is terminated by the Company within one (1) year
                  following
                  a Change of Control, and such termination is without Cause, then
                  you shall
                  be entitled to receive, in addition to all compensation due and
                  payable to
                  or accrued (which includes milestone based bonus achievements)
                  as of the
                  date of termination, your annual compensation, payable in semi-monthly
                  installments over a period of twelve (12) months in accordance
                  with the
                  Company’s normal payroll practices in effect at such time, and any and
                  all
                  outstanding options to purchase shares of stock in the Company
                  granted to
                  you shall immediately vest and become immediately exercisable (whether
                  entered into before or after the date of this Agreement), in addition
                  to
                  the Company’s healthcare and insurance benefits program over a period of
                  twelve (12) months. 

              

      

    

     

    
      VioQuest
        Pharmaceuticals, Inc.

      180
        Mt. Airy Road, Suite 102

      Basking
        Ridge, NJ 07920

      Telephone:
        +1 908 766 4400 Fax: +1 908 766 4455 

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

    

     

    

      
        	
                

              	
                 

              	
                VioQuest

                PHARMACEUTICALS,
                  INC.

              

      

    

    
 

    
      
        	
              	9.	
                You
                  represent to the Company that your employment with the Company
                  will not
                  constitute a breach or other violation of any agreement or contract
                  under
                  which you are bound or any other obligation that you owe to any
                  third
                  party. You further represent that no approvals or consents are
                  required
                  from any third party (including any former employer) in order for
                  you to
                  be employed by the Company as contemplated by this letter. To ensure
                  that
                  you comply with any possible obligations you may have to your former
                  employer(s), the Company requests that you check your past employment
                  records to determine whether, at any time within the last 3 years,
                  you
                  signed an agreement pertaining to any of the
                  following:

              

      

    

     

    
      	·  	
              Limiting
                in any way your ability to compete with your former employer(s) or
                work
                for the Company;

            

    

     

    
      	·  	
              Promising
                not to solicit any of your former co-workers or colleagues to join
                you as
                an employee of a future employer;

            

    

     

    
      	·  	
              Promising
                not to solicit or call upon any of the customers of any of your former
                employer(s);

            

    

     

    
      	·  	
              Promising
                not to use or share any confidential or proprietary information belonging
                to your former employer(s); or

            

    

     

    
      	·  	
              Agreeing
                to return any confidential or proprietary information belonging to
                your
                former employer(s).

            

    

     

    If
      your
      review of your past employment records reveals that you have any agreements
      described above, or any other agreements similar to those described above,
      please provide documents to the undersigned so that the Company may
      review.

     

    
      
        	
              	10.	
                In
                  addition to this Letter, it is a condition of your employment that
                  you
                  agree to be bound by the Company’s other established policies and
                  procedures, including the Company’s code of ethics and employee manual. In
                  particular, you hereby acknowledge the provisions of the employee
                  manual
                  set forth under the caption “Confidentiality and Intellectual Property
                  Assignment Agreement” and agree that you will be bound by the terms of
                  such section (as well as the other provisions of the employee manual).
                  As
                  a further condition, you will need to complete the Federal Employment
                  Eligibility Verification Form I-9 (please bring acceptable documents
                  with
                  you on the Effective Date that verify your identity and eligibility
                  to
                  work in the United States).

              

      

    

     

    
      VioQuest
        Pharmaceuticals, Inc.

      180
        Mt. Airy Road, Suite 102

      Basking
        Ridge, NJ 07920

      Telephone:
        +1 908 766 4400 Fax: +1 908 766 4455 

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

    

     

    

      
        	
                

              	
                 

              	
                VioQuest

                PHARMACEUTICALS,
                  INC.

              

      

    

     

    
      
        	
              	11.	
                You
                  agree during your term of employment with the Company and for twelve
                  months following the end of your employment, you will not solicit
                  the
                  business of, interfere with, disrupt, or attempt to disrupt, the
                  Company's
                  business relationship with, any of its clients or investors, or
                  solicit
                  any of the Company's employees.

              

      

    

     

    
      
        	
              	12.	
                You
                  shall receive 20 business days as vacation
                  days.

              

      

    

    

    
      
        	
              	13.	
                Your
                  title at the Company shall be Chief Scientific and Medical Officer,
                  responsible for successfully designing, implementing, and reporting
                  the
                  Company’s clinical trials to shareholders, potential investors, Board of
                  Directors and management, and to ensure the clinical trials meet
                  the
                  highest standards of excellence for ethics, scientific merit and
                  regulatory compliance, as well as satisfy corporate goals and meet
                  timeliness for approval. You will report to the President and
                  CEO.

              

      

    

    

    This
      offer for employment is valid until February 1, 2007. If the Company does not
      receive a response by you as of this date, the offer will expire.

    

    If
      you
      find the foregoing arrangement acceptable and believe that the foregoing
      accurately summarizes our understanding, please kindly so indicate by executing
      and dating the attached copy of this letter in the space provided and returning
      a copy to me.

     

    
      	 	 	 	Very
              truly
              yours,
	 	 	 	 
	 	 	 	VioQuest Pharmaceuticals, Inc. 
	 	 	 	 
	
            	 	 	/s/ Daniel Greenleaf
	ACCEPTED
&
              AGREED	 	 	
              
Daniel
              Greenleaf
	
            	 	 	President and CEO
	/s/ Edward C. Bradley	 	 	 
	
              
Edward
              C. Bradley, M.D.	 	 	 

    

     

    
      VioQuest
        Pharmaceuticals, Inc.

      180
        Mt. Airy Road, Suite 102

      Basking
        Ridge, NJ 07920

      Telephone:
        +1 908 766 4400 Fax: +1 908 766 4455

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00116-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00116-of-00352.parquet"}]]